The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Structural Investigation Into The Regulation Of The Colony Stimulating Factor Receptor, C-FMS.
Funder
National Health and Medical Research Council
Funding Amount
$287,321.00
Summary
The colony stimulating factor receptor, c-FMS is a member of a family of protein signalling molecules expressed on the cell surface that are implicated in the development of serious diseases in humans, such as inflammatory diseases and cancer. A number of important proteins bind to and regulate c-FMS in different ways. I intend to visualise these interactions to further understand how c-FMS activity is controlled by alternative means.
Structural Studies Of The Jak And Abl Kinases: A Prerequisite For Drug Design
Funder
National Health and Medical Research Council
Funding Amount
$360,965.00
Summary
Protein tyrosine kinases (PTK) are a large, pivotal family of signalling molecules implicated in diseases such as cancer and immune related disorders. This fellowship aims to develop more potent kinase inhibitors of a number of PTKs using Cytopia’s drug discovery capability coupled with the X-ray crystallography expertise within Monash University. This innovative approach will permit a rational structure-based drug discovery platform to be established and will lead to the creation of a portfolio ....Protein tyrosine kinases (PTK) are a large, pivotal family of signalling molecules implicated in diseases such as cancer and immune related disorders. This fellowship aims to develop more potent kinase inhibitors of a number of PTKs using Cytopia’s drug discovery capability coupled with the X-ray crystallography expertise within Monash University. This innovative approach will permit a rational structure-based drug discovery platform to be established and will lead to the creation of a portfolio of phase I therapeutics, which will be of substantial benefit in the medical health area.Read moreRead less
Structure Determination Of Fms And Kit Kinases And Their Inhibtors For Directed Drug Design
Funder
National Health and Medical Research Council
Funding Amount
$373,250.00
Summary
Tyrosine kinases are a large and important family of enzymes that play a fundamental role in the control and communication between cells. When damaged or uncontrolled, these enzymes can contribute to the development of diseases such as cancer and immune related disorders. This proposal aims to develop therapeutics targeted at the tyrosine kinases using a combination of the Structure Biology expertise at Monash University and the drug discovery platform technologies of Cytopia Pty Ltd. Promising ....Tyrosine kinases are a large and important family of enzymes that play a fundamental role in the control and communication between cells. When damaged or uncontrolled, these enzymes can contribute to the development of diseases such as cancer and immune related disorders. This proposal aims to develop therapeutics targeted at the tyrosine kinases using a combination of the Structure Biology expertise at Monash University and the drug discovery platform technologies of Cytopia Pty Ltd. Promising drug candidates already identified by Cytopia will be analysed at their site of action using X-ray crystallography. This information will enable a rational process of modification and improvement of the candidate drugs. The development of a range of therapeutics for Phase I clinical trials will be of enormous benefit to Australia�s medical industry and pubic health.Read moreRead less